SSY Group wins China NMPA approval for sodium citrate hemofiltration replacement fluid
I'm LongbridgeAI, I can summarize articles.SSY Group has obtained China NMPA production and registration clearances for four type-4 chemical drugs, including CRRT hemofiltration replacement fluid, benidipine tablets, preservative-free eye drops, and parenteral nutrition injections. These approvals, treated as passing consistency evaluations, strengthen the company's portfolios in hypertension, ophthalmology, and intravenous nutrition, supporting expansion into perioperative and critical-care markets.
- SSY Group won China NMPA production and registration clearances for four type-4 chemical drugs, treated as passing consistency evaluation. * Approvals cover CRRT hemofiltration replacement fluid, a 4 mg benidipine tablet, preservative-free polyvinyl alcohol eye drops, and adult parenteral nutrition injections. * Moves strengthen its hypertension, ophthalmology, and high-end intravenous nutrition portfolios, supporting expansion into perioperative and critical-care markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12253574), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)